Teva in talks to merge with Allergan's generic unit
Following hot on the heels of the US Supreme Court's decision to uphold the 2010 Affordable Care Act, and in the face of increased competition in the arena for treatments against multiple-sclerosis, Teva Pharmaceuticals may announce a merger with part of Allergan as early as Monday, The Wall Street Journal reported.
ANTHEM
$142.05
22:15 04/09/15
CIGNA Corp.
$354.51
11:10 25/04/24
Mylan Inc.
$0.00
19:30 08/12/22
Nasdaq 100
17,430.50
12:05 25/04/24
Perrigo Company plc
$31.27
10:59 25/04/24
The Israeli generic drugs maker is seeking to merge with the big generic-drug business of its US rival, according to people familiar with the matter.
A successful transaction, valued at approximately $45bn, would allow Teva, the world's largest seller of generic medicines, to achieve cost savings and help it cope with already razor-thin margins, creating a $60bn beheamoth.
It would also follow merger announcements worth $82bn by four of America's largest managed-care companies: Anthem Inc. with Cigna Corp. and Aetna with Humana Inc..
Teva has been unsuccessful in its attempts to woo Mylan NV, who in turn has been focused on pursuing fellow drug-maker Perrigo, even as the $70bn a year market for generics has been slowing.